GH: Bernstein Reinstates Outperform
Bernstein analyst Eve Burstein reinstates Guardant Health with an Outperform rating and $175 price target.
Bernstein analyst Eve Burstein reinstates Guardant Health (NASDAQ: GH ) with a Outperform and announces $175 price target.